Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Yerushalmi

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Nano Letters|June 9, 2022
Atomic and Molecular Layer Deposition of Chiral Thin Films Showing up to 99% Spin Selective TransportH Al-Bustami, S Khaldi, O Shoseyov, et al.
Neoplasma|December 15, 2006
Radiation treatment for ductal carcinoma in situ (DCIS): is a boost to the tumor bed necessary?R Yerushalmi, A Sulkes, M Mishaeli, et al.
British Journal of Cancer|May 5, 2005
Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell linesO Uziel, E Fenig, J Nordenberg, et al.
Bone Marrow Transplantation|November 21, 2007
Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphomaA Shimoni, S T Zwas, Y Oksman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2000
Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantationY Nieto, P J Cagnoni, S Nawaz, et al.
Bone Marrow Transplantation|May 17, 2016
Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantationP Tsirigotis, I Danylesko, K Gkirkas, et al.
Breast Cancer Research and Treatment|May 27, 2016
Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutationsR Lewin, A Sulkes, T Shochat, et al.
Breast Cancer Research and Treatment|October 12, 2013
Do alternative methods of measuring tumor size, including consideration of multicentric/multifocal disease, enhance prognostic information beyond TNM staging in women with early stage breast cancer: an analysis of the NCIC CTG MA.5 and MA.12 clinical trialsJ F Hilton, N Bouganim, B Dong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 6, 2017
Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trialsR Yerushalmi, B Dong, J W Chapman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2018
Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trialJ Ettl, R G W Quek, K-H Lee, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Nano Letters|June 9, 2022
Atomic and Molecular Layer Deposition of Chiral Thin Films Showing up to 99% Spin Selective TransportH Al-Bustami, S Khaldi, O Shoseyov, et al.
Neoplasma|December 15, 2006
Radiation treatment for ductal carcinoma in situ (DCIS): is a boost to the tumor bed necessary?R Yerushalmi, A Sulkes, M Mishaeli, et al.
British Journal of Cancer|May 5, 2005
Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell linesO Uziel, E Fenig, J Nordenberg, et al.
Bone Marrow Transplantation|November 21, 2007
Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphomaA Shimoni, S T Zwas, Y Oksman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2000
Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantationY Nieto, P J Cagnoni, S Nawaz, et al.
Bone Marrow Transplantation|May 17, 2016
Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantationP Tsirigotis, I Danylesko, K Gkirkas, et al.
Breast Cancer Research and Treatment|May 27, 2016
Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutationsR Lewin, A Sulkes, T Shochat, et al.
Breast Cancer Research and Treatment|October 12, 2013
Do alternative methods of measuring tumor size, including consideration of multicentric/multifocal disease, enhance prognostic information beyond TNM staging in women with early stage breast cancer: an analysis of the NCIC CTG MA.5 and MA.12 clinical trialsJ F Hilton, N Bouganim, B Dong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 6, 2017
Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trialsR Yerushalmi, B Dong, J W Chapman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2018
Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trialJ Ettl, R G W Quek, K-H Lee, et al.
Pageof 4